Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study

Journal of Clinical Psychopharmacology

Volumn 18, Issue 1, 1998, Pages 2-9

  Wetzel, Hermann ^a   Anghelescu, Ion ^a   Szegedi, Armin ^a   Wiesner, Jasmin ^a   Weigmann, Harald ^a   Härtter, Sebastian ^a   Hiemke, Christoph ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CLOZAPINE DERIVATIVE; CLOZAPINE N OXIDE; DRUG METABOLITE; FLUVOXAMINE; NORCLOZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; ELECTROENCEPHALOGRAM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HYPERSALIVATION; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SMOKING; SOLID PHASE EXTRACTION; STEADY STATE; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG INTERACTIONS; FEMALE; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS; SMOKING;

EID: 0031963522     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199802000-00002     Document Type: Article

References (44)

1. Peacock L, Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J Clin Psychiatry 1994; 55:44-9.
2. Naber D, Holzbach R, Perro C, Hippius H. Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry Suppl 1992;17:54-9.
3. Siris SG, Bermanzohn PC, Mason SE, Shuwall MA. Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Arch Gen Psychiatry 1994;51:109-15.
4. Baumann P, Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol 1995;1[suppl 10]:15-21.
5. Goff DC, Baldessarini RJ. Drug interactions with antipsychotic agents. J Clin Psychopharmacol 1993;13:57-63.
6. Shader RI, von Moltke LL, Schmider J, Harmatz JS, Greenblatt DJ. The clinician and drug interactions - an update. J Clin Psychopharmacol 1996;16:197-201.
7. Cassady SL, Thaker GK. Addition of fluoxetine to clozapine [letter]. Am J Psychiatry 1992;149:1274.
8. Dequardo JR, Roberts M. Elevated clozapine levels after fluvoxamine initiation. Am J Psychiatry 1996;153:840-1.
9. Eggert AE, Crismon ML, Dorson PG. Lack of effect of fluoxetine on plasma clozapine concentrations [letter]. J Clin Psychiatry 1994:55:10.
10. Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994;14:279-81.
11. Szegedi A, Wiesner J, Hiemke C. Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J Clin Psychopharmacol 1995;15:141-3.
12. Jerling M, Lindström L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
13. DuMortier G, Lochu A, Colen de Melo P, Ghribri O, Roche-Rabreau D, DeGrassat K, Desce JM. Elevated clozapine plasma concentrations after fluvoxamine initiation. Am J Psychiatry 1996;153:738-9.
14. Jann M, Grimsley S, Gray E, Chang W. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24:161-76.
15. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995;272:984-90.
16. Fischer V, Vogels B, Maurer G, Tynes R. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther 1992; 260:1355-60.
17. Tugnait M, Hawes EM, McKay G, Rettie AE, Haining RL, Midha KK. N-oxygenation of clozapine by flavin-containing monooxygenase. Drug Metab Dispos Biol Fate Chem 1997;25:524-7.
18. Wilde MI, Plosker GL, Benfield P. Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness. Drugs 1993;46:895-924.
19. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P450 1A2. Biochem Pharmacol 1993;45:1211-1.
20. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, Harmatz JS, Shader RI. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology (Berl) 1996;128:398-407.
21. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RJ. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-31.
22. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 1994;55[suppl 12]:38-45.
23. Glue P, Banfleld C. Psychiatry, psychopharmacology and P-450s. Hum Psychopharmacol 1996;11:97-114.
24. Preskorn SH. Reducing the risk of dug-drug interactions: a goal of rational drug development. J Clin Psychiatry 1996;57[suppl 1]:3-6.
25. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24:203-20.
26. Hiemke C. Paroxetin: Pharmakokinetik und Pharmakodynamik. Fortschr Neurol Psychiatr 1994;62[suppl 1]:2-8.
27. Sindrup SHK, Brøsen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen AD, Cooper SM, Mellows TCG, Tasker BD, Zussman BD. The relationship between paroxetine and sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:288-95.
28. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
29. 1C receptor antagonists. Eur J Pharmacol 1993;245:179-82.
30. 2C serotonin receptors. Nature 1995;374:542-6.
31. Gerson SL, Arce C, Meltzer HY. N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. Br J Haematol 1994;86:555-61.
32. Härtter S, Wetzel H, Hammes E, Hiemke C. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology (Berl) 1993;110:302-8.
33. Weigmann H, Hiemke C. Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1992; 583:209-16.
34. Bertilsson L, Carrillo JA, Dahl ML, Llerena A, Aim C, Bondesson U, Lindstrom L, Rodriguez de la Rubia I, Ramos S, Benitez J. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:71-3.
35. Jeppesen U, Loft S, Poulsen HE, Brøsen K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996;6:213-22.
36. Funderburg LG, Vertrees JE, True JE, Miller AL. Seizure following addition of erythromycin to clozapine treatment. Am J Psychiatry 1994;151:1840-1.
37. Szegedi A, Wetzel H, Leal M, Härtter S, Hiemke C. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety and tolerability data. J Clin Psychiatry 1996;57:257-64.
38. Dahl ML, Llerena A, Bondesson U, Lindstrom L, Bertilsson L. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 1994;37:71-4.
39. Arranz MJ, Dawson E, Shaikh S, Sham P, Sharma T, Aitchison K, Crocq MA, Gill M, Kerwin R, Collier DA. Cytochrome P4502D6 genotype dose not determine response to clozapine. Br J Clin Pharmacol 1995;39:417-20.
40. Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996;153:820-2.
41. Physicians' scientific information (Wissenschaftliche Fachinformation für Ärzte). Nuremberg, Germany: Sandoz-Wander Pharma, April 1996.
42. Choc MG, Hsuan F, Honigfeld G, Robinson WT, Ereshefsky L, Crismon ML, Saklad SR, Hirschowitz J, Wagner R. Single- vs. multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res 1990;347-51.
43. Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, Flood JG. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine of valproate. Am J Psychiatry 1994;151: 123-5.
44. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin reuptake inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38:23-31.